| Full Name | Protein Kinase AMP-Activated Catalytic Subunit Alpha 2 |
| Gene Symbol | PRKAA2 (AMPKα2, AMPK) |
| Chromosomal Location | 1p32.2 |
| NCBI Gene ID | [5563](https://www.ncbi.nlm.nih.gov/gene/5563) |
| OMIM | [600497](https://omim.org/entry/600497) |
| Ensembl | [ENSG00000162409](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162409) |
| UniProt (Protein) | [P54646 (5'-AMP-activated protein kinase catalytic subunit alpha-2)](https://www.uniprot.org/uniprot/P54646) |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Huntington's Disease](/diseases/huntingtons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), Type 2 Diabetes |
PRKAA2 (Protein Kinase AMP-Activated Catalytic Subunit Alpha 2) encodes the α2 catalytic subunit of AMP-activated protein kinase (AMPK), the master cellular energy sensor and metabolic regulator. AMPK is a heterotrimeric complex comprising a catalytic α subunit (PRKAA1/α1 or PRKAA2/α2), a scaffolding β subunit (PRKAB1/β1 or PRKAB2/β2), and a regulatory γ subunit (PRKAG1/γ1, PRKAG2/γ2, or PRKAG3/γ3). When cellular ATP is depleted and AMP/ADP levels rise, AMPK is activated and phosphorylates hundreds of downstream targets to restore energy homeostasis by stimulating catabolic pathways (glucose uptake, fatty acid oxidation, autophagy, mitophagy) and suppressing anabolic pathways (protein synthesis via mTORC1 inhibition, lipogenesis, gluconeogenesis).
In the brain, PRKAA2/AMPKα2 is the predominant catalytic isoform in neurons, where it plays essential roles in synaptic plasticity, axonal energy supply, mitochondrial quality control, and neuronal survival under metabolic stress. AMPK dysregulation is a convergent pathomechanism across major neurodegenerative diseases, making PRKAA2 a high-priority therapeutic target.
PRKAA2 spans approximately 93 kb on chromosome 1p32.2 and contains 12 exons. The promoter region contains binding sites for PGC-1α, CREB, MEF2, and FOXO transcription factors. Alternative splicing produces minor transcript variants, but the canonical 552 amino acid isoform predominates.
In the brain, PRKAA2 is the major α-subunit isoform in neurons, with highest expression in the hypothalamus (particularly the arcuate nucleus), hippocampus (CA1, CA3, dentate gyrus), cerebral cortex, and cerebellum. PRKAA1/α1 predominates in astrocytes and microglia, while both isoforms are expressed in oligodendrocytes. The hypothalamic enrichment of PRKAA2 reflects its critical role in whole-body energy sensing and appetite regulation. The Allen Brain Atlas confirms neuronal enrichment across cortical layers and hippocampal subfields.
AMPKα2 is a 552 amino acid serine/threonine kinase containing an N-terminal kinase domain, an auto-inhibitory domain (AID), an α-linker region with the β-subunit-interacting domain (β-SID), and a C-terminal domain (CTD) that binds the β and γ subunits.
AMPK activation requires phosphorylation of Thr172 in the α-subunit activation loop, which is accomplished by three upstream kinases:
AMP and ADP bind the γ subunit (CBS domains), causing conformational changes that: (i) promote Thr172 phosphorylation by LKB1, (ii) inhibit Thr172 dephosphorylation by protein phosphatases (PP2A, PP2C), and (iii) allosterically activate the kinase up to 10-fold. ATP competes for the same binding sites, so AMPK is a ratiometric sensor of AMP:ATP and ADP:ATP.
AMPK phosphorylates over 100 substrates. The most neurologically relevant include:
PRKAA2/AMPKα2 is particularly important at synapses, where it acts as a local energy gauge:
AMPK dysregulation is a prominent feature of AD, with both insufficient and excessive AMPK activity contributing to pathology at different stages:
Beneficial AMPK roles in AD:
Detrimental AMPK roles in AD:
Postmortem AD brains show elevated activated AMPK (phospho-Thr172) co-localizing with tangle-bearing neurons in the hippocampus and entorhinal cortex. AMPKα2 is the predominant isoform in these neurons, suggesting PRKAA2 specifically drives the pathological tau phosphorylation.
In PD, AMPK plays a largely protective role through its regulation of mitophagy and mitochondrial quality control:
In MPTP and rotenone PD models, AMPK is acutely activated as a compensatory response to Complex I inhibition. Short-term AMPK activation is protective, but sustained activation (reflecting chronic energy failure) correlates with dopaminergic neuron loss. AMPKα2-specific knockout in midbrain dopaminergic neurons accelerates MPTP-induced neurodegeneration, confirming a predominantly neuroprotective role.
Huntingtin (HTT)))))))))) aggregates in HD impair mitochondrial function and energy metabolism, leading to chronic AMPK activation in striatal medium spiny neurons. AMPK activation in HD has dual consequences:
AMPK is activated in motor neurons of ALS patients and SOD1-G93A mice. AMPKα2 activation in motor neurons enhances TDP-43 phosphorylation and promotes stress granule formation, potentially contributing to the gain-of-toxic-function mechanism. However, AMPK-driven autophagy is beneficial for clearing TDP-43 and FUS aggregates. The net effect appears to be disease-stage dependent.
PRKAA2 mutations and polymorphisms are associated with type 2 diabetes, metabolic syndrome, and obesity. Brain insulin resistance — a feature of AD sometimes called "type 3 diabetes" — involves impaired insulin-mediated AMPK regulation. Metformin, the most widely prescribed antidiabetic drug, activates AMPK and has shown epidemiological association with reduced dementia risk.
| Variant | Type | Association | Reference |
|---|---|---|---|
| rs2796498 | Intronic | Type 2 diabetes susceptibility | Horikoshi et al., 2006 |
| rs2796516 | Intronic | Metabolic syndrome, insulin resistance | Spencer-Jones et al., 2006 |
| c.1547G>A (R516Q) | Missense | Reduced kinase activity, Wolff-Parkinson-White variant | Arad et al., 2007 |
| rs10789038 | Intronic | Nominal association with hippocampal volume | Genome-wide studies |
Given AMPK's dual roles (protective autophagy vs. detrimental tau phosphorylation), therapeutic AMPK modulation in neurodegeneration requires:
| Brain Region | Expression Level | Cell Types |
|---|---|---|
| Hypothalamus (arcuate nucleus) | Very High | Neurons (AGRP, POMC) |
| Hippocampus (CA1, CA3, DG) | High | Pyramidal neurons, granule cells |
| Cerebral cortex | Moderate-High | Pyramidal neurons, interneurons |
| Cerebellum | Moderate | Purkinje cells, granule neurons |
| Substantia nigra | Moderate | Dopaminergic neurons |
| Striatum | Moderate | Medium spiny neurons |
| Spinal cord | Moderate | Motor neurons |